Longeveron Inc. last reported quarterly results on Aug 12, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $287,000 (-9.2% year over year) and diluted EPS of -$0.19. It usually reports 35–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 3, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Nov 4, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 12, 2026
43 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
-9.2%
|
-6
-20.8%
|
-0.19
+42.4%
|
|
May 13, 2026
43 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
+4.5%
|
-5
+5.5%
|
-0.19
+44.1%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
-82.3%
|
-7
-63.4%
|
-0.39
-14.7%
|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
-32.5%
|
-5
-47.3%
|
-0.33
+82.0%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
0
-30.5%
|
-5
-23.5%
|
-0.34
+78.9%
|
|
Feb 28, 2025
59 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
1
+857.1%
|
-4
+32.3%
|
-0.00
+89.3%
|
|
Nov 12, 2024
43 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
1
+415.3%
|
-4
+13.5%
|
-0.34
+87.8%
|
|
Aug 14, 2024
45 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LGVN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1721484
- Former names
- LONGEVERON LLC (until Feb 10, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.